The hypothalamo-neurohypophysial complex in organ culture: effects of metabolic inhibitors, biologic and pharmacologic agents.
Organ cultures of the guinea pig hypothalamo-neurohypophysial complex synthesize the octapeptide hormone, vasopressin, a specific product of the neurosecretory cells of the supraoptic nucleus. Inhibitors of both protein and RNA synthesis (cycloheximide and bromotubercidin respectively) were found to block vasopressin biosynthesis. In the presence of bromotubercidin, the apparent half-time of decline in the rate of hormone biosynthesis was about 28 h. Colchicine inhibited the distal transport of vasopressin into the posterior pituitary. Ultrastructural studies on colchicine-treated cultures indicated the neuronal stalks were intact and that neurotubules were still present. The narcotic drug, levorphanol at 10-7 M and 10-9 M was found to inhibit RNA synthesis by 20 percent. At these concentrations it had no demonstrable effect on vasopressin synthesis. Cultures established from animals that had been rendered tolerant to narcotics also had no observable alterations in vasopressin biosynthesis, although the initial pituitary vasopressin content of these cultures was reduced by about 35 percent. Various pharmacologic and biologic compounds were tested for their effects on vasopressin biosynthesis in organ cultures. Dibutyryl cyclic AMP, estradiol-17beta, nicotine, nerve growth factor (NGF), and pineal extract all had no effects under the present experimental regimen. Medium conditioned by the presence of fetal hypothalami of 40-55 days gestation produced a 2-4 fold increase in vasopressin biosynthesis in cultures established from adult animals. Medium conditioned by fetal cerebral cortex, liver, or hypothalamic tissue from fetuses of less than 33 days gestation did not have this stimulatory effect.
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000963:Antimetabolites / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D001966:Bromine / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002540:Cerebral Cortex / Q000502:physiology; D003078:Colchicine / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology*; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D004958:Estradiol / Q000494:pharmacology; D005865:Gestational Age; D006207:Half-Life; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000378:metabolism; D007031:Hypothalamus / Q000502:physiology; D007981:Levorphanol / Q000494:pharmacology; D009414:Nerve Growth Factors / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology; D009924:Organ Culture Techniques; D010870:Pineal Gland / Q000502:physiology; D010902:Pituitary Gland / Q000648:ultrastructure; D010904:Pituitary Gland, Posterior / Q000378:metabolism; D011691:Puromycin / Q000494:pharmacology; D012313:RNA / Q000096:biosynthesis; D014667:Vasopressins / Q000096:biosynthesis*
D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D009414:Nerve Growth Factors; D014667:Vasopressins; D007981:Levorphanol; D011691:Puromycin; D004958:Estradiol; D012313:RNA; D003994:Bucladesine; D009538:Nicotine; D003513:Cycloheximide; D001966:Bromine; D003078:Colchicine